Iovance hits two-year high after raising annual revenue forecast
IOVA•Iovance raised its FY2026 revenue outlook to $410 million-$420 million from $350 million-$370 million, and shares rose 27.5% to their highest level in more than two years.
1. Higher revenue outlook
Iovance raised its FY2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million. The CEO said record second-quarter results and sustained demand for Amtagvi and Proleukin led the company to raise its full-year guidance by $55 million at the midpoint.
